#JPM23 kicks off with an acquisition as Chiesi inks all-cash $1B+ deal for Amryt

As many of the industry’s bigwigs arrive in the Bay Area to hash out deals, Chiesi Farmaceutici is showing up with an all-cash acquisition in the bag. The Italian drug developer said Sunday it is buying rare disease biotech Amryt Pharma for $1.25 billion. Amryt is the maker of four…

...

Click to view original post